SS Innovations Reports Strong Preliminary 2025 Revenue Growth and Anticipates Key Regulatory Milestones

summarizeResumen

The company's preliminary results indicate robust operational momentum, with full-year 2025 revenue more than doubling compared to the previous year. This strong performance, driven by increased installations of its SSi Mantra surgical robotic system, underscores the growing adoption of its cost-effective technology. The anticipated regulatory clearances from the U.S. FDA and for the European CE Mark in the first half of 2026 are critical catalysts, paving the way for significant market expansion into major global healthcare markets. Investors should monitor the final audited results and the progress of these regulatory approvals, which could substantially impact the company's future growth trajectory.

check_boxEventos clave

• Preliminary Full Year 2025 Revenue

  Reported approximately $43.0 million, a 108% increase from $20.6 million in 2024.

• Preliminary Q4 2025 Revenue

  Announced approximately $15.0 million, an 85% increase from $8.1 million in Q4 2024.

• SSi Mantra Installations

  Cumulative installed base reached 168 systems by December 31, 2025, up 158% year-over-year, with 103 installations in 2025.

• Anticipated Regulatory Milestones

  Expects U.S. FDA 510(k) premarket notification review and European Union CE marking certification for the SSi Mantra in the first half of 2026.

auto_awesomeAnalisis

The company's preliminary results indicate robust operational momentum, with full-year 2025 revenue more than doubling compared to the previous year. This strong performance, driven by increased installations of its SSi Mantra surgical robotic system, underscores the growing adoption of its cost-effective technology. The anticipated regulatory clearances from the U.S. FDA and for the European CE Mark in the first half of 2026 are critical catalysts, paving the way for significant market expansion into major global healthcare markets. Investors should monitor the final audited results and the progress of these regulatory approvals, which could substantially impact the company's future growth trajectory.